Avtor/Urednik		Kyrgiou, Maria; Arbyn, Marc; Bergeron, Christine; Bosch, Francesc Xavier; Dillner, J.; Jit, Mark; Poljak, Mario; Nieminen, Pekka; Sasieni, Peter; Kesić, Vesna
Naslov		Cervical screening
Tip		članek
Vol. in št.		Letnik 123, št. 4
Leto izdaje		2020
Obseg		str. 510-517
ISSN		0007-0920 - British Journal of Cancer
Jezik		eng
Abstrakt		This paper summarises the position of ESGO and EFC on cervical screening based on existing guidelines and opinions of a team of lead experts. HPV test is replacing cytology as this offers greater protection against cervical cancer and allows longer screening intervals. Only a dozen of HPV tests are considered as clinically validated for screening. The lower specificity of HPV test dictates the use of triage tests that can select women for colposcopy. Reflex cytology is currently the only well validated triage test; HPV genotyping and p16 immunostaining may be used in the future, although methylation assays and viral load also look promising. A summary of quality assurance benchmarks is provided, and the importance to audit the screening histories of women who developed cancer is noted as a key objective. HPV-based screening is more cost-effective than cytology or cotesting. HPV-based screening should continue in the post-vaccination era. Only a fraction of the female population is vaccinated, and this varies across countries. A major challenge will be to personalise screening frequency according to vaccination status. Still the most important factor for successful prevention by screening is high population coverage and organised screening. Screening with self-sampling to reach under-screened women is promising.
Proste vsebinske oznake		test HPV maternični vrat ginekološka onkologija PSA HPV test cervix gynaecologic oncology